Consistent with this, Bcl‐2 family molecular signatures, including Bcl‐xl, Bcl‐2, Noxa, and Bcl‐w, correctly predict susceptibility to N of 70% of small‐cell lung cancers and 81% of leukemias and lymphomas (Tahir et al., 2010; Vo et al., 2012). This evidence concerns the gene BCL2 and lymphoma.